XML 60 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Note 8 - Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Mar. 16, 2020
Mar. 31, 2023
Jun. 30, 2022
Aug. 31, 2019
Mar. 31, 2018
Dec. 31, 2022
Dec. 31, 2021
Operating Lease, Weighted Average Remaining Lease Term (Year)           4 years 2 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent           9.60%  
Research and Development Expense, Total           $ 18,968,000 $ 14,418,000
Employee Agreements, Termination Benefits Provided To Key Employees, Aggregate Amount           900,000  
Houston Pharmaceuticals, Inc [Member]              
Related Party Transaction, Expenses from Transactions with Related Party             234,000
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member]              
Other Commitment, Total $ 43,500            
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member]              
Other Commitment, Total $ 15,000            
Other Commitments, Cancellation Period (Day) 60 days            
IPX Memorial Drive Investors LLC [Member]              
Lessee, Operating Lease, Term of Contract (Month)         66 months    
Lessee, Operating Lease, Renewal Term (Year)         5 years    
Olympia Drive W Bellfort LLC [Member]              
Operating Lease, Rent Expense, Annual Increase In Rent, Percent       3.00% 3.00%    
Houston Pharmaceuticals, Inc [Member]              
Percentage of Rent Payable By Co-Lessee       50.00%      
Percentage Of Sub-lease Income Allocable To Co-lessee       50.00%      
Sublease Income           45,000 42,000
MD Anderson [Member]              
License Agreements Expense           264,000 267,000
Payments For Research And Development Agreement     $ 1,300,000        
Research and Development Expense, Total           1,133,000 $ 697,000
MD Anderson [Member] | Maximum [Member]              
License Agreement Annual License Fee           100,000  
MD Anderson [Member] | Maximum [Member] | Submission Of N D A And Receipt Of First Marketing Approval For Sale Of A Licensed Product [Member]              
Milestone Payment Liabilities           $ 600,000  
WPD Pharmaceuticals [Member] | Subsequent Event [Member]              
Payments for Termination of Commitment   $ 700,000          
Stock Issued During Period, Value, Termination of Agreement   $ 800,000